New transplant method aims to cut dangerous side effects in blood cancer patients

NCT ID NCT05800210

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and young adults with blood cancers like leukemia and lymphoma. Researchers will compare the rate of severe graft-versus-host disease to historical data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
stem cell transplant with T-cell and B-cell removal
What this could lead to
If successful, this could offer a safer stem cell transplant option for blood cancer patients, reducing severe side effects while controlling the disease.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply broadly. The procedure carries risks like infection or graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Florida

    RECRUITING

    Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.